Martin is Chair of Syncona Investment Management Ltd. He co-founded Syncona with the Wellcome Trust in 2012. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Azeria Therapeutics. He was previously Chairman of former Syncona company Blue Earth Diagnostics, and before that, he was a partner at venture capital company MVM Life Science Partners LLP, leading their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

Share Share It FB TW GP